SUTRO BIOPHARMA, INC. - 8-K Filing

Sutro Biopharma reports Q3 2026 revenue of $9.1 million and $142.2 million in cash reserves, projecting runway into H1 2028. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits (d) Exhibits)

SEC EDGAR · November 12, 2026, 21:45 UTC

Tickers: $STRO

Read the full article at SEC EDGAR

More Regulatory news

SCHWAB CHARLES CORP - 8-K Filing SEC EDGAR · November 12, 2026, 21:52 UTC
SPRUCE POWER HOLDING CORP - 8-K Filing SEC EDGAR · November 12, 2026, 21:52 UTC
Xterax Corp II - 10-Q Filing SEC EDGAR · November 12, 2026, 21:51 UTC
KinderCare Learning Companies, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:50 UTC
Finwise Bancorp - 8-K Filing SEC EDGAR · November 12, 2026, 21:49 UTC
TMC the metals Co Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:48 UTC
FACT II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:46 UTC
Marblegate Capital Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 21:46 UTC
Greenland Mines Ltd - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
InspireMD, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC